Page last updated: 2024-09-05

lapatinib and Amenorrhea

lapatinib has been researched along with Amenorrhea in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrios, CH; Baselga, J; Bines, J; Boyle, F; Campbell, C; de Azambuja, E; Del Mastro, L; Fumagalli, D; Gelber, RD; Ignatiadis, M; Izquierdo, M; Jackisch, C; Korde, LA; Lambertini, M; Lang, I; Moreno-Aspitia, A; Piccart, M; Pritchard, K; Smith, I; Untch, M; Wolff, AC; Xu, B	1

Trials

1 trial(s) available for lapatinib and Amenorrhea

Article	Year
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. Journal of the National Cancer Institute, 2019, 01-01, Volume: 111, Issue:1 Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Premenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab	2019

Article

Year

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Journal of the National Cancer Institute, 2019, 01-01, Volume: 111, Issue:1

Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Premenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab

2019